Feasibility of iNKT cell and PD-1+CD8+ T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical immunology"
DOI: 10.1016/j.clim.2022.108992
Abstract: We performed a single-arm exploratory clinical trial that is ongoing and registered at ClinicalTrials.gov (NCT03093688). Patients were infused with autologous iNKT cells, PD-1 + CD8+ T cells, and dendritic cells every 3-5 weeks, which was considered 1 cycle. The… read more here.
Keywords: response; clinical trial; preliminary results; inkt cell ... See more keywords